Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ETTXNASDAQ:PRTANASDAQ:PRTCNASDAQ:VERV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeETTXEntasis Therapeutics$2.19$2.19$1.40▼$3.88$104.80M1.33239,104 shs800 shsPRTAProthena$6.58+0.5%$9.67$6.36▼$25.42$354.18M0.11601,836 shs1.71 million shsPRTCPureTech Health$18.20-4.2%$17.22$13.30▼$32.98$437.15M1.144,708 shs1,376 shsVERVVerve Therapeutics$4.36-0.5%$4.61$2.86▼$9.31$388.66M1.821.86 million shs1.38 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceETTXEntasis Therapeutics0.00%0.00%0.00%0.00%0.00%PRTAProthena+0.46%-8.36%-31.39%-57.71%-69.52%PRTCPureTech Health+2.94%+6.31%+6.18%-0.25%-38.31%VERVVerve Therapeutics-0.46%-5.83%-20.29%-40.11%-22.14%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationETTXEntasis TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/APRTAProthena3.8096 of 5 stars4.43.00.00.03.91.71.3PRTCPureTech Health2.1316 of 5 stars3.84.00.00.02.40.00.0VERVVerve Therapeutics3.5001 of 5 stars4.51.00.00.03.83.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceETTXEntasis Therapeutics 0.00N/AN/AN/APRTAProthena 2.88Moderate Buy$51.71685.93% UpsidePRTCPureTech Health 3.50Strong Buy$45.00147.25% UpsideVERVVerve Therapeutics 3.00Buy$25.75490.60% UpsideCurrent Analyst Ratings BreakdownLatest ETTX, PRTC, VERV, and PRTA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2025PRTAProthenaCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/9/2025PRTAProthenaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$48.00 ➝ $30.005/9/2025PRTAProthenaJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$80.00 ➝ $78.005/9/2025PRTAProthenaChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.00 ➝ $40.004/15/2025VERVVerve TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$18.00 ➝ $24.004/15/2025VERVVerve TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Overweight4/15/2025VERVVerve TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$32.00 ➝ $39.004/14/2025VERVVerve TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$15.00 ➝ $25.003/25/2025VERVVerve TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy3/25/2025VERVVerve TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.003/4/2025VERVVerve TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$17.00 ➝ $15.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookETTXEntasis Therapeutics$7M14.97N/AN/A$0.66 per share3.32PRTAProthena$137.94M2.57N/AN/A$10.46 per share0.63PRTCPureTech Health$4.32M101.31N/AN/A$16.94 per share1.07VERVVerve Therapeutics$59.61M6.52N/AN/A$7.31 per share0.60Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateETTXEntasis Therapeutics-$47.14M-$1.12N/AN/AN/AN/A-145.48%-103.75%N/APRTAProthena-$147.03M-$2.08N/AN/AN/A-90.50%-22.67%-19.68%N/APRTCPureTech Health-$65.70MN/A0.00N/AN/AN/AN/AN/AN/AVERVVerve Therapeutics-$200.07M-$2.11N/AN/AN/A-807.65%-35.23%-27.65%N/ALatest ETTX, PRTC, VERV, and PRTA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025VERVVerve Therapeutics-$0.71-$0.35+$0.36-$0.35$7.13 million$32.98 million5/8/2025Q1 2025PRTAProthena-$0.92-$1.12-$0.20-$1.12$8.18 million$2.83 million2/27/2025Q4 2024VERVVerve Therapeutics-$0.72-$0.58+$0.14-$0.58$3.94 million$13.08 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthETTXEntasis TherapeuticsN/AN/AN/AN/AN/APRTAProthenaN/AN/AN/AN/AN/APRTCPureTech HealthN/AN/AN/AN/AN/AVERVVerve TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioETTXEntasis TherapeuticsN/A1.651.65PRTAProthenaN/A11.5211.52PRTCPureTech HealthN/A3.68N/AVERVVerve TherapeuticsN/A13.0513.05Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipETTXEntasis Therapeutics6.91%PRTAProthena97.08%PRTCPureTech Health0.04%VERVVerve Therapeutics97.11%Insider OwnershipCompanyInsider OwnershipETTXEntasis Therapeutics6.50%PRTAProthena9.20%PRTCPureTech Health5.30%VERVVerve Therapeutics19.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableETTXEntasis Therapeutics5147.85 million44.74 millionNot OptionablePRTAProthena13053.83 million38.64 millionOptionablePRTCPureTech Health10024.02 million22.67 millionNot OptionableVERVVerve Therapeutics11089.14 million68.32 millionOptionableETTX, PRTC, VERV, and PRTA HeadlinesRecent News About These CompaniesGroundbreaking treatment for bad cholesterol on the horizon? This single-use drug shows some promiseMay 24 at 5:33 AM | cnbctv18.comStrokes and Heart Attacks Kill. New Drugs Are Coming to Prevent Them.May 23 at 2:22 PM | msn.comHC Wainwright Has Optimistic Outlook of VERV FY2025 EarningsMay 23 at 8:29 AM | marketbeat.comMillennium Management LLC Sells 1,105,050 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV)May 23 at 4:00 AM | marketbeat.comFY2025 EPS Estimate for Verve Therapeutics Lifted by AnalystMay 23 at 2:27 AM | americanbankingnews.comWhat is HC Wainwright's Estimate for VERV FY2026 Earnings?May 22 at 7:40 AM | marketbeat.comResearch Analysts Offer Predictions for VERV FY2026 EarningsMay 22 at 2:40 AM | americanbankingnews.com3 Top Genomics Stocks to Add to Your Portfolio in 2025May 21 at 10:05 AM | zacks.comVerve Therapeutics, Inc. (NASDAQ:VERV) Position Raised by Vestal Point Capital LPMay 21 at 8:23 AM | marketbeat.comPoint72 Asset Management L.P. Buys New Position in Verve Therapeutics, Inc. (NASDAQ:VERV)May 21 at 5:20 AM | marketbeat.comVerve Therapeutics Leads The Charge With 2 Other Promising Penny StocksMay 20, 2025 | finance.yahoo.comTema Etfs LLC Invests $503,000 in Verve Therapeutics, Inc. (NASDAQ:VERV)May 20, 2025 | marketbeat.comCantor Fitzgerald Analysts Raise Earnings Estimates for VERVMay 20, 2025 | americanbankingnews.comCantor Fitzgerald Issues Positive Outlook for VERV EarningsMay 20, 2025 | marketbeat.comQ3 EPS Forecast for Verve Therapeutics Lifted by AnalystMay 20, 2025 | marketbeat.comQ3 EPS Forecast for Verve Therapeutics Raised by AnalystMay 20, 2025 | americanbankingnews.comAnalyst Forecasts For Verve Therapeutics, Inc. (NASDAQ:VERV) Are Surging HigherMay 19, 2025 | finance.yahoo.comVerve Therapeutics, Inc. (NASDAQ:VERV) Given Average Recommendation of "Buy" by BrokeragesMay 19, 2025 | americanbankingnews.comThe MAGA revolution threatens America’s most innovative placeMay 18, 2025 | economist.comCubist Systematic Strategies LLC Has $663,000 Position in Verve Therapeutics, Inc. (NASDAQ:VERV)May 18, 2025 | marketbeat.comVERVE-102: A single-course gene editing therapy for permanent inactivation of PCSK9May 16, 2025 | bioworld.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongBy Sam Quirke | May 13, 2025View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongWhy D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumNVIDIA Stock Surges on Bullish News: How High Could It Climb?By Thomas Hughes | May 13, 2025View NVIDIA Stock Surges on Bullish News: How High Could It Climb?Broadcom: Buy, Hold, Sell? AI & Acquistions Paint Strong PictureBy Leo Miller | May 1, 2025View Broadcom: Buy, Hold, Sell? AI & Acquistions Paint Strong PictureETTX, PRTC, VERV, and PRTA Company DescriptionsEntasis Therapeutics NASDAQ:ETTXEntasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial products to treat serious infections caused by multidrug-resistant pathogens in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. The company also develops Zoliflodacin, a novel orally administered molecule, which is in Phase III clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant gram-negative infections. The company has a license and collaboration agreement with Zai Lab (Shanghai) Co., Ltd. for the development of durlobactam and SUL-DUR; and collaboration agreement with Global Antibiotic Research and Development Partnership for the development and commercialization of a product candidate zoliflodacin. Entasis Therapeutics Holdings Inc. was founded in 2015 and is headquartered in Waltham, Massachusetts. Entasis Therapeutics Holdings Inc. operates as a subsidiary of Innoviva, Inc.Prothena NASDAQ:PRTA$6.58 +0.03 (+0.46%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$4.98 -1.60 (-24.30%) As of 05/23/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.PureTech Health NASDAQ:PRTC$18.20 -0.80 (-4.21%) Closing price 05/23/2025 03:59 PM EasternExtended Trading$18.08 -0.13 (-0.69%) As of 05/23/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.Verve Therapeutics NASDAQ:VERV$4.36 -0.02 (-0.46%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$4.36 0.00 (0.00%) As of 05/23/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/19 - 05/23 Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
